Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt?
Recently failed antiamyloidogenic trials call for an objective reassessment of the dominating amyloid cascade hypothesis of Alzheimer’s disease (AD). Ongoing efforts focusing on amyloid β protein (Aβ), its deposition, and its removal need to be complemented by more intensive research in new directio...
Gespeichert in:
| Veröffentlicht in: | Trends in pharmacological sciences (Regular ed.) 2017-10, Vol.38 (10), p.849-851 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 851 |
|---|---|
| container_issue | 10 |
| container_start_page | 849 |
| container_title | Trends in pharmacological sciences (Regular ed.) |
| container_volume | 38 |
| creator | Behl, Christian |
| description | Recently failed antiamyloidogenic trials call for an objective reassessment of the dominating amyloid cascade hypothesis of Alzheimer’s disease (AD). Ongoing efforts focusing on amyloid β protein (Aβ), its deposition, and its removal need to be complemented by more intensive research in new directions. Those may either integrate amyloid pathology or will propose pathogenetic routes independent of Aβ in the search for the causes of AD. |
| doi_str_mv | 10.1016/j.tips.2017.07.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1931251747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165614717301414</els_id><sourcerecordid>1931251747</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-f392d0499d79bbcdc359d8c720fb88ced48c6daef449155706d278ce97b22393</originalsourceid><addsrcrecordid>eNp9kM1Kw0AUhQdRbK2-gAvJ0k3q_CSZGREktlqFgiDdD8nMDU7JT80kQlz5Gr6eT-KUVpfChQuH7xzuPQidEzwlmCRX62lnN25KMeFT7AfTAzQmgrOQcRYforGH4jAhER-hE-fWGGPGKDlGIyoETWIRj1GaVkPZWBPYOkjLj1ewFbTfn18umFsHmYPrYNHbshuCOxia2gQvXmzqLC8hmDd93t2eoqMiKx2c7fcErR7uV7PHcPm8eJqly1CzOOnCgklqcCSl4TLPtfGqNEJziotcCA0mEjoxGRRRJEkcc5wYyr0ueU4pk2yCLnexm7Z568F1qrJOQ1lmNTS9U0QyQmPCI-5RukN12zjXQqE2ra2ydlAEq21zaq22zaltcwr7wdSbLvb5fV6B-bP8VuWBmx0A_sl3C61y2kLtL7ct6E6Zxv6X_wPnHX-M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1931251747</pqid></control><display><type>article</type><title>Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Behl, Christian</creator><creatorcontrib>Behl, Christian</creatorcontrib><description>Recently failed antiamyloidogenic trials call for an objective reassessment of the dominating amyloid cascade hypothesis of Alzheimer’s disease (AD). Ongoing efforts focusing on amyloid β protein (Aβ), its deposition, and its removal need to be complemented by more intensive research in new directions. Those may either integrate amyloid pathology or will propose pathogenetic routes independent of Aβ in the search for the causes of AD.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/j.tips.2017.07.002</identifier><identifier>PMID: 28826585</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Amyloid - metabolism ; Animals ; Humans</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 2017-10, Vol.38 (10), p.849-851</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-f392d0499d79bbcdc359d8c720fb88ced48c6daef449155706d278ce97b22393</citedby><cites>FETCH-LOGICAL-c356t-f392d0499d79bbcdc359d8c720fb88ced48c6daef449155706d278ce97b22393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tips.2017.07.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28826585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Behl, Christian</creatorcontrib><title>Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt?</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>Recently failed antiamyloidogenic trials call for an objective reassessment of the dominating amyloid cascade hypothesis of Alzheimer’s disease (AD). Ongoing efforts focusing on amyloid β protein (Aβ), its deposition, and its removal need to be complemented by more intensive research in new directions. Those may either integrate amyloid pathology or will propose pathogenetic routes independent of Aβ in the search for the causes of AD.</description><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Amyloid - metabolism</subject><subject>Animals</subject><subject>Humans</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1Kw0AUhQdRbK2-gAvJ0k3q_CSZGREktlqFgiDdD8nMDU7JT80kQlz5Gr6eT-KUVpfChQuH7xzuPQidEzwlmCRX62lnN25KMeFT7AfTAzQmgrOQcRYforGH4jAhER-hE-fWGGPGKDlGIyoETWIRj1GaVkPZWBPYOkjLj1ewFbTfn18umFsHmYPrYNHbshuCOxia2gQvXmzqLC8hmDd93t2eoqMiKx2c7fcErR7uV7PHcPm8eJqly1CzOOnCgklqcCSl4TLPtfGqNEJziotcCA0mEjoxGRRRJEkcc5wYyr0ueU4pk2yCLnexm7Z568F1qrJOQ1lmNTS9U0QyQmPCI-5RukN12zjXQqE2ra2ydlAEq21zaq22zaltcwr7wdSbLvb5fV6B-bP8VuWBmx0A_sl3C61y2kLtL7ct6E6Zxv6X_wPnHX-M</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Behl, Christian</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt?</title><author>Behl, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-f392d0499d79bbcdc359d8c720fb88ced48c6daef449155706d278ce97b22393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Amyloid - metabolism</topic><topic>Animals</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Behl, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Behl, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt?</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>2017-10</date><risdate>2017</risdate><volume>38</volume><issue>10</issue><spage>849</spage><epage>851</epage><pages>849-851</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>Recently failed antiamyloidogenic trials call for an objective reassessment of the dominating amyloid cascade hypothesis of Alzheimer’s disease (AD). Ongoing efforts focusing on amyloid β protein (Aβ), its deposition, and its removal need to be complemented by more intensive research in new directions. Those may either integrate amyloid pathology or will propose pathogenetic routes independent of Aβ in the search for the causes of AD.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28826585</pmid><doi>10.1016/j.tips.2017.07.002</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-6147 |
| ispartof | Trends in pharmacological sciences (Regular ed.), 2017-10, Vol.38 (10), p.849-851 |
| issn | 0165-6147 1873-3735 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1931251747 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Alzheimer Disease - metabolism Alzheimer Disease - pathology Amyloid - metabolism Animals Humans |
| title | Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A46%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amyloid%20in%20Alzheimer%E2%80%99s%20Disease:%20Guilty%20Beyond%20Reasonable%20Doubt?&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Behl,%20Christian&rft.date=2017-10&rft.volume=38&rft.issue=10&rft.spage=849&rft.epage=851&rft.pages=849-851&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/j.tips.2017.07.002&rft_dat=%3Cproquest_cross%3E1931251747%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1931251747&rft_id=info:pmid/28826585&rft_els_id=S0165614717301414&rfr_iscdi=true |